文献速递慢性肾脏病

重塑肾脏病机制试验:以组织为中心的多模态方法解析司美格鲁肽肾脏作用机制

REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
PubMed 文献 · Kidney Int · 2025-11-07

慢性肾脏病是全球重大健康负担,也是2型糖尿病常见并发症。REMODEL试验(NCT04865770)采用功能磁共振成像、研究性肾活检及血尿生物标志物分析的多参数方法,探索司美格鲁肽在2型糖尿病合并慢性肾脏病患者中的肾脏保护机制,旨在解释FLOW试验(NCT03819153)的肾脏获益并识别优化治疗的患者亚群。

要点

  • REMODEL试验整合功能MRI、肾活检和生物标志物多模态评估司美格鲁肽肾脏机制
  • 该设计旨在解释FLOW试验中司美格鲁肽的肾脏获益并识别治疗优势亚群
  • 文章描述REMODEL框架、方法、技术挑战与经验,为未来机制试验提供平台

核心结论

  • REMODEL试验采用多参数方法探索司美格鲁肽的肾脏作用机制,以解释其肾脏结局获益并识别优化治疗的患者亚群。

研究设计与样本

  • REMODEL试验(NCT04865770)为机制性试验,在2型糖尿病合并慢性肾脏病患者中整合功能磁共振成像、研究性肾活检和血尿生物标志物分析。

临床怎么用

  • 通过多模态机制试验深入理解司美格鲁肽的肾脏保护作用,可能指导患者亚群选择和个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease poses a major global health burden and is one of the most common complications of type 2 diabetes. Drug trials have demonstrated that treatments, including sodium-glucose cotransporter-2 inhibitors, a glucagon-like peptide-1 receptor agonist, and a nonsteroidal mineralocorticoid receptor antagonist, mitigate chronic kidney disease progression, but the underlying nephroprotective mechanisms of action remain incompletely understood, partly ascribed to their pleiotropic actions. New innovative trial designs are needed to tackle simultaneously the hemodynamic and structural effects induced by these drugs. The REMODEL trial (REnal MODE of action of semagLutide in patients with type 2 diabetes and chronic kidney disease; ClinicalTrials.gov identifier: NCT04865770) is designed to explore the mechanisms of action of semaglutide with a novel multiparametric approach, integrating functional magnetic resonance imaging and research kidney biopsies for structural and molecular interrogation and blood and urine biomarker analysis. Better understanding of these mechanisms will help explain semaglutide's beneficial effects on kidney disease outcomes, reported in the FLOW (Evaluate Renal Function with Semaglutide Once Weekly; ClinicalTrials.gov identifier: NCT03819153) trial, and may identify patient subpopulations to optimize treatment strategies. By combining diverse and state-of-the-art methods, REMODEL aims to pave the way to a larger use of mechanism of action trials in the near future. To this purpose, this article describes the REMODEL framework, methods, technical challenges, and lessons learned as a platform for future mechanistic trials of chronic kidney disease therapies and beyond.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Pruijm M, Belmar N, Bjornstad P, et al. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2025. PMID: 41207620. doi:10.1016/j.kint.2025.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。